4Q21 Wrap: the bleeding continues
Biopharmas continued to slump in 4Q21 across all market cap tiers
Biopharma stocks continued to spiral downwards across all market cap tiers in 4Q21. Megacaps showed the least amount of bleeding with a median loss in market cap of 5%, while microcaps lost a median of 19%.
French diagnostics player bioMerieux S.A. (Euronext:BIM) led gainers in the megacap group, defined as companies that started the quarter with valuations of $10 billion or more. The company had a 25% jump in its market cap following news that its tests can detect the Omicron variant of SARS-CoV-2...
BCIQ Company Profiles
BCIQ Target Profiles